23 December, 2017 (All day)

Asahi Kasei Pharma call for applications (research grant 50000 $) / deadline 22 December / target:  EU researchers

Asahi Kasei Pharma ( Asahi-Kasei-Pharma-company-presentation.pdf ) is looking for partnerships with European technology counterparts.

This is an open competition, and the objective is to target new potential areas for growth and mutual benefits.
Asahi Kasei Pharma believes “locomotive syndrome” to be a serious problem that needs to be urgently addressed in our aging society.
For this reason, the company dedicates their research and development efforts toward developing new drugs that help patients worldwide who are suffering from chronic pain, metabolic bone diseases, or rheumatoid arthritis. The company is a leader in the field of these disorders and have thus far developed the synthetic calcitonin derivative Elcitonin®, the human parathyroid hormone preparation Teribone®, and the immunosuppressant Bredinin®.

In the future, Asahi Kasei Pharma will continue their efforts to generate a steady flow of new innovative drugs.

To achieve this, the company aims to build a larger pipeline of new drug candidates through collaboration with our research partners and further strengthen our drug development capabilities in the areas of orthopedics and musculoskeletal disorders.

Details of areas of Interest and Specific Research Needs and Topics is available on: Asahi-Kasei-Pharma-Call-for-Proposal.docx

 

Award amounts (research grant) and Collaboration Period

Award amounts will be determined individually for each application and will not exceed a maximum of US $50,000 for one year.

The collaboration period is generally limited to one year. However, based on demonstrated project success, funding for an additional one-year period may be granted.

For any query on the call, would you please directly contact drug-seeds@om.asahi-kasei.co.jp email with the EU-Japan Centre - Mariko Ashida: m.ashida@eu-japan.eu in Cc.

Application form available on: Asahi-Kasei-Pharma-Application-form.docx

Type: 
Research
Sector: 
Biotechnology
Source: 
Asahi Kasei Pharma
Contact e-mail: 
Mariko Ashida: M.Ashida@eu-japan.eu